(Q44403147)

2 December 2017

title

Empiric therapy with moxalactam alone in patients with bacteremia (English)

1 reference

2 December 2017

W R Wilson

1

1 reference

2 December 2017

N K Henry

2

1 reference

2 December 2017

T F Keys

3

1 reference

2 December 2017

J P Anhalt

4

1 reference

2 December 2017

F R Cockerill

5

1 reference

2 December 2017

R S Edson

6

1 reference

2 December 2017

J E Geraci

7

1 reference

2 December 2017

P E Hermans

8

1 reference

2 December 2017

S M Muller

9

1 reference

2 December 2017

J E Rosenblatt

10

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 May 1984

1 reference

2 December 2017

1 reference

2 December 2017

volume

59

1 reference

2 December 2017

issue

5

1 reference

2 December 2017

page(s)

318-326

1 reference

Clinical evaluation of moxalactam

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Therapy of obstetrical infections with moxalactam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Moxalactam therapy for bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Therapy of lower respiratory tract infections with moxalactam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Clinical evaluation of moxalactam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Moxalactam therapy for a wide spectrum of bacterial infections in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958-1966.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

7 January 2021

Polymicrobial bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Clinical Evaluation of Moxalactam in the Treatment of Respiratory Tract Infections, Hepatobiliary Infections, and Septicemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Moxalactam in the therapy of serious infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Clinical evaluation of moxalactam therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Moxalactam: Clinical Summary of Efficacy and Safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Pharmacokinetics and Clinical Efficacy of Moxalactam in Biliary Tract Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

A turbidimetric study of the responses of selected strains of Pseudomonas aeruginosa to eight antipseudomonal beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

The new beta-lactamase-stable cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Moxalactam in the Treatment of Intraabdominal Sepsis and Other Surgical Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Effects of Moxalactam on Blood Coagulation and Platelet function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

Moxalactam Therapy vs. Standard Antimicrobial Therapy for Selected Serious Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Enterococcal Infections in Patients Treated with Moxalactam

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Treatment of Intraabdominal Infection with Moxalactam

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961427-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-6196(12)61427-X

1 reference

2 December 2017

1 reference